Strategies in maintenance for patients receiving long-term therapy (SIMPLE): A study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis

Inflammatory Bowel Diseases

Volumn 18, Issue 6, 2012, Pages 1026-1033

  Kane, Sunanda ^a   Katz, Seymour ^b   Jamal, M Mazen ^c,h   Safdi, Michael ^d   Dolin, Ben ^e   Solomon, Dory ^f   Palmen, Mary ^g   Barrett, Karen ^g  

^a MAYO CLINIC   (United States)

^b Long Island Clinical Research Associates   (United States)

^c VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^d Greater Cincinnati OB/GYN   (United States)

^e Illinois Gastroenterology Institute   (United States)

^f SHIRE   (United States)

^g Shire Pharmaceuticals   (United Kingdom)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

5 aminosalicylic acid; MMX mesalamine; ulcerative colitis

Indexed keywords

MESALAZINE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ADULT; ANXIETY DISORDER; ARTICLE; BACKACHE; CHI SQUARE TEST; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FATIGUE; FEMALE; GASTROENTERITIS; HEADACHE; HEMORRHOID; HUMAN; HYPERCHOLESTEROLEMIA; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; RASH; RECURRENT DISEASE; RHINOPHARYNGITIS; SCREENING; SINUSITIS; TREATMENT PLANNING; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; MEDICATION ADHERENCE; MESALAMINE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; RISK FACTORS; TIME FACTORS;

EID: 84861334530     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21841     Document Type: Article

References (22)

1. Carter MJ, Lobo AJ, Travis SP,. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004; 53: V1-16.
2. Kornbluth A, Sachar DB,. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010; 105: 501-523.
3. Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001; 96: 2929-2933.
4. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003; 114: 39-43.
5. Bassi A, Dodd S, Williamson P, et al. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut. 2004; 53: 1471-1478.
6. Janke KH, Klump B, Gregor M, et al. Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis. 2005; 11: 272-286.
7. Kane SV,. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006; 23: 577-585.
8. Loftus EV Jr,. A practical perspective on ulcerative colitis: patients' needs from aminosalicylate therapies. Inflamm Bowel Dis. 2006; 12: 1107-1113.
9. Tenjarla S, Romasanta V, Zeijdner E, et al. Release of 5-aminosalicylate from the MMX mesalamine tablet during transit through a simulated gastrointestinal tract system. Adv Ther. 2007; 24: 826-840.
10. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily high concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007; 132: 66-75.
11. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007; 5: 95-102.
12. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomized trial of once- or twice-daily MMX™ mesalamine for maintenance of remission in ulcerative colitis. Gut. 2008; 57: 893-902.
13. Sandborn WJ, Korzenik J, Lashner B, et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology. 2010; 138: 1286-1296.
14. Dignass AU, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2009; 7: 762-9.
15. Shale MJ, Riley SA,. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003; 18: 191-198.
16. Loftus EV,. Patients' experiences of living with ulcerative colitis: findings from a large survey of the Crohn's and Colitis Foundation of America (CCFA). Am J Gastroenterol. 2006; 101 (abstract 1104).
17. Kane SV,. Overcoming adherence issues in ulcerative colitis. Gastroenterol Hepatol. 2007; 3: 795-799.
18. Hanauer SB, Sninsky CA, Robinson M, et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized, placebo-controlled trial. Ann Intern Med. 1996; 124: 204-211.
19. Ireland A, Mason CH, Jewell DP,. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut. 1988; 29: 835-837.
20. Kruis W, Judmaier G, Kayasseh L, et al. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. Eur J Gastroenterol Hepatol. 1995; 7: 391-396.
21. Miner P, Hanauer S, Robinson M, et al. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci. 1995; 40: 296-304.
22. Rutgeerts P,. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group. Aliment Pharmacol Ther. 1989; 3: 183-191.